Correlation between HER2\neu, ER&PR status and histological stage in breast cancer

Background: The aim of this study is to understand the HERR-2/neu over expression and its correlation with ER&PR status and histological stage in breast cancer.
A total of 328 women were selected retrospectively from this group the tissue samples of breast cancer had been analyzed using immunohistochemical techniques for HERR-2/neu over expression and ER&PR status.
Objective: To evaluate the expression of tumor markers (HER2/neu) with ER&PR status and histological stage in breast cancer.
Results: The correlation between HER-2/neu overexpression and ER&PR status in stage I – III B breast cancer.  HER-2/neu–ve and ER +ve cases are (81%), whereas HER-2/neu+ve and ER +ve cases are (19%). While HER-2/neu–ve and ER –ve cases are (72%), compared to HER-2/neu+ve and ER –ve which are (28%). HER-2/neu–ve and PR +ve cases are 87 (84%), whereas HER-2/neu+ve and PR +ve cases are 17 (16%). Whereas HER-2/neu–ve and PR –ve cases are 132 (62%), and HER-2/neu+ve and PR –ve are 42 (38%). The correlation between HER-2/neu overexpression and ER&PR status in stage IV breast cancer. HER-2/neu–ve and ER +ve cases are (100%), whereas HER-2/neu+ve and ER +ve cases are (0%). Whereas, HER-2/neu–ve and ER –ve cases are (50%), and HER-2/neu+ve and ER –ve which are (50%). HER-2/neu–ve and PR +ve cases are (0%), whiles HER-2/neu+ve and PR+ve cases are (100%). Whereas HER-2/neu–ve and PR –ve cases are (60%), and HER-2/neu+ve and PR –ve are (40%). The correlation between HER-2/neu overexpression and ER&PR status in stage I – IV breast cancer.  HER-2/neu–ve and ER+ve cases are (82%), while HER-2/neu+ve and ER +ve cases are (18%). Whereas, HER-2/neu–ve and ER–ve cases are (69%), and HER-2/neu+ve and ER–ve which are (31%). HER-2/neu–ve and PR +ve cases are (82%) and HER-2/neu+ve and PR +ve cases are (18%). Whereas, HER-2/neu–ve and PR –ve cases are (74%), and HER-2/neu+ve and PR –ve are (26%).
Conclusion: In this study population, the HER-2/neu expression its relation with ER&PR status and histological stage in breast cancer determined.